AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Reuters· July 14, 2026

AstraZeneca has reached an agreement to license a lung cancer drug from China-based Dizal Pharmaceutical. The partnership underscores the strategic importance of Chinese biotech innovations in the global oncology landscape. This acquisition aims to bolster AstraZeneca's existing pipeline of lung cancer treatments and expand its therapeutic offerings.

Read the full story at Reuters

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Reuters.

More in Pharmaceutical

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

AstraZeneca has secured an exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a novel oral EGFR inhibitor targeting specific lung cancer mutations. The therapy is currently approved in the United States and China for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who have progressed after chemotherapy. This deal strengthens AstraZeneca's oncology portfolio by addressing a significant unmet need in the targeted treatment landscape for genetically driven lung cancers.

July 14, 2026

Wytheville man arrested in NC on felony prescription drug theft charges

A Virginia man has been apprehended in North Carolina following an investigation into the theft of prescription narcotics from a nursing home facility. Brian Travis Wingler faces more than 15 felony charges related to the incident, which involved a multi-agency effort between the Wytheville Police Department and the Iredell County Sheriff’s Office. The case highlights significant security and diversion risks within the pharmaceutical distribution chain at the point of care.

July 14, 2026

Q&A: What Will It Take to Reshore US Drug Manufacturing?

The pharmaceutical industry is currently evaluating the strategic requirements and logistical hurdles associated with reshoring drug manufacturing to the United States. This inquiry addresses the need for domestic production capabilities to safeguard the supply of essential medicines against global disruptions. Determining the necessary policy and infrastructure changes is a priority for industry leaders aiming to strengthen the national pharmaceutical supply chain and reduce reliance on foreign suppliers.

July 14, 2026

FDA Approves Subcutaneous Formulation of Leqembi Iqlik

The U.S. Food and Drug Administration has approved a subcutaneous formulation of the Alzheimer's treatment Leqembi, branded as Leqembi Iqlik, which allows for at-home administration via a weekly autoinjector. This regulatory milestone is accompanied by significant deal-making in the oncology space, as AstraZeneca secured global rights to Dizal Pharmaceutical's lung cancer therapy Zegfrovy in a transaction valued at up to $1.5 billion. These developments underscore a dual industry focus on improving patient access through convenient delivery systems and strengthening pipelines in targeted oncology.

July 14, 2026